News Archive
As the largest international academic Institute dedicated to cancer, the LICR believes that it has a moral obligation to assist in the responsible dissemination and reporting of credible and timely research news and views.
May 5, 2008
New Player in Colon Cancer Genesis Identified
In a study published today in Cancer Cell, a group led by LICR Affiliate Dr. Kari Alitalo (Helsinki, Finland), identified the PROX1 protein as a key driver of colon cancer tumorigenesis.
April 28, 2008
Richard Kolodner Elected to American Academy of Arts and Sciences
Dr. Richard D. Kolodner, LICR’s Executive Director of Laboratory Science and Technology and a Member of the LICR San Diego Branch, was today elected a Fellow of the prestigious American Academy of Arts and Sciences.
April 15, 2008
LICR’s First Spin-off Company Acquired by Roche
PIramed, the first spin-off company from the Ludwig Institute for Cancer Research, was today acquired by the pharmaceutical company, Roche. PIramed was formed in 2003 to exploit inhibitors targeting the PI-3 kinase family of enzymes. The inhibitors - and most of the PI-3 kinases - were first characterized by a group led by the Founding Director of the LICR London Branch, Michael D. Waterfield, F.R.S.
February 12, 2008
Ludwig Institute for Cancer Research receives Largest 2009 Grant from NHMRC
The National Health & Medical Research Council (NHMRC) of Australia has awarded its largest grant for 2009 to the Ludwig Institute for Cancer Research (LICR) in Melbourne.
February 4, 2008
Resisting Lung Cancer Recurrence
What if we could prevent cancer recurrence for years after surgery by giving simple recall injections every two or three years? This concept may no longer be a fantasy. In a clinical study published online this week by the Proceedings of the National Academy of Sciences USA, a team headed by the international Ludwig Institute for Cancer Research (LICR) has shown that a vaccine against a protein found in cancer cells produces an immune response that can be boosted and strengthened with additional vaccine shots.
November 19, 2007
Immune system can drive cancers into dormant state
A multinational team of researchers, which includes LICR New York Branch Director, Dr. Lloyd J. Old, has shown for the first time that the immune system can stop the growth of a cancerous tumor without actually killing it.
November 4, 2007
Ludwig Institute for Cancer Research to set up its first Asian branch in Singapore
A memorandum of understanding (MOU) has been signed by the worlds largest international non-profit cancer research institute, the Ludwig Institute for Cancer Research (LICR), to establish a branch for translational and clinical cancer research in Singapore. This is in collaboration with three Singapore institutions, namely, the Agency for Science, Technology and Research (A*STAR), the Yong Loo Lin School of Medicine of the National University of Singapore (YLL-NUS) and the Duke-NUS Graduate Medical School (Duke-NUS GMS).
October 8, 2007
Webster K. Cavenee elected to Institute of Medicine
Dr. Webster Cavenee, Director of the LICR San Diego Branch, was today elected as a Member of the Institute of Medicine. Established in 1970 by the National Academy of Sciences, the Institute has become recognized as a national resource for independent, scientifically informed analysis and recommendations on human health issues.
June 14, 2007
Brazil’s first oncology biotech launches
Recepta, Brazil’s first oncology biotechnology company was launched today by PR&D, a Brazilian venture capital company, and the international non-profit Ludwig Institute for Cancer Research (LICR). The company will explore the therapeutic potential of three antibodies discovered and characterized by LICR.
June 5, 2007
Largest ever Phase III lung cancer trial based on LICR discovery
GSK has announced the launch of the largest ever Phase III trial in lung cancer treatment, which is based on the MAGE-A3 cancer-testis antigen discovered by the Ludwig Institute for Cancer Research. Results from a Phase II trial showed that the cancer vaccine, or ‘antigen-specific cancer immunotherapy (ASCI),’ showed a 27% reduction in the relative risk of recurrence of non-small cell lung cancer (NSCLC) following surgery.